Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Invivyd, Inc. (IVVD) CEO to present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference to discuss the company's mission to protect against viral infectious diseases and host investor meetings. The live webcast will be available on the company's website.
02/05/2024 - 04:02 PM
WALTHAM, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that David Hering, Chief Executive Officer of Invivyd, is scheduled to present in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024 at 1:00 p.m. ET in New York, NY.
In addition to the fireside chat, the management team will host investor meetings at the conference. Investors participating in the conference who are interested in meeting with Invivyd management should contact their Guggenheim representative.
A live webcast of the fireside chat will be available in the investor section of the company's website at investors.invivyd.com and will be archived for approximately 30 days following the presentation.
About Invivyd Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. The company’s proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. Leveraging its INVYMAB platform approach, the company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications. Visit https://invivyd.com/ to learn more.
Contacts:
Scott Young (781) 208-1747syoung@invivyd.com
Gabriella Linville-Engler (781) 208-0160gengler@invivyd.com
What is the mission of Invivyd, Inc. (IVVD)?
Invivyd, Inc. (IVVD) is on a mission to protect the vulnerable from serious viral infectious diseases.
When and where is the CEO of Invivyd, Inc. (IVVD) scheduled to present?
The CEO of Invivyd, Inc. (IVVD) is scheduled to present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024, at 1:00 p.m. ET in New York, NY.
Where can investors watch the live webcast of the fireside chat?
Investors can watch the live webcast of the fireside chat in the investor section of the company's website at investors.invivyd.com.
How long will the webcast be available for viewing?
The webcast will be archived for approximately 30 days following the presentation.
IVVD Rankings
#4901 Ranked by Stock Gains
IVVD Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
About IVVD
adagio is developing best-in-class antibodies that can broadly neutralize sars-cov-2, sars-cov-1 and additional potentially emergent coronaviruses. we believe our antibodies will match or exceed the potency and coverage of conventional sars-cov-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments. our candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. our portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. our lead program is expected to enter the clinic by the end of 2020.